Physician profile
Wayne Barber
NPI 1245233428
$3,103.97
in general payments reported to CMS, 2019-2025
25 companies · $598 in 2025
The $598 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $306 · 2021: $266 · 2022: $252 · 2023: $482 · 2024: $509 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $579.65 | 2019-2025 | Clareon, Tryptyr, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $473.37 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $349.28 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $304.89 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $250.54 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.12 | 2019-2021 | |
| Allergan, INC. | $155.10 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $117.70 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Mallinckrodt Hospital Products INC. | $116.94 | 2021-2024 | Acthar |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Astellas Pharma US INC | $53.41 | 2024 | Izervay |
| Abbvie INC. | $51.90 | 2022 | |
| Harrow Eye, LLC | $47.67 | 2024 | Vevye |
| Amgen INC. | $47.22 | 2024-2025 | Tepezza |
| Dompe US, INC. | $45.87 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $37.22 | 2020-2021 | |
| Omeros Corporation | $32.88 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $30.10 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $23.91 | 2022 | |
| Shire North American Group INC | $18.89 | 2019 | |
| Ocular Therapeutix, INC. | $18.21 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $16.55 | 2023 | Tepezza |
| Glaukos Corporation | $15.62 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Thea Pharma INC. | $14.96 | 2024 | Iyuzeh |
| Biotissue Holdings INC. | $13.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.